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Abstract
Introduction
Tuberculosis anatomical classification is inconsistent in the literature, which limits current
tuberculosis knowledge and control. We aimed to evaluate whether tuberculosis classifica-
tion impacts on treatment outcomes at patient and aggregate level.
Methods
We analyzed adults from São Paulo State, Brazil with newly diagnosed tuberculosis from
2010–2013. We used an extended clinical classification of tuberculosis, categorizing cases
as pulmonary, pulmonary and extrapulmonary, extrapulmonary and miliary/disseminated.
Our primary outcome was unsuccessful outcome of treatment. To investigate the reported
treatment outcome at the aggregate level, we sampled 500 different “countries” from the
dataset and compared the impact of pulmonary and extrapulmonary classifications on the
reported treatment success.
Results
Of 62,178 patients, 49,999 (80.4%) were pulmonary, 9,026 (14.5%) extrapulmonary,
1,651 (2.7%) pulmonary-extrapulmonary and 1,502 (2.4%) miliary/disseminated. Pulmo-
nary-extrapulmonary cases had similar unsuccessful outcome of treatment compared with
pulmonary (adjusted-OR 1.00, 95%CI, 0.88–1.13, p = 0.941), while extrapulmonary were
associated with better (adjusted-OR 0.65, 95%CI, 0.60–0.71, p<0.001) and miliary/dissemi-
nated with worse outcomes (adjusted-OR 1.51, 95%CI, 1.33–1.71, p<0.001). We found that
60 (12%) countries would report a difference10% in treatment success depending on
whether they reported all clinical forms together (current WHO recommendation) or pulmo-
nary forms alone, overestimating the treatment success of pulmonary forms.
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Conclusions
The expanded anatomical classification of tuberculosis was strongly associated with treat-
ment outcomes at the patient level. Remarkably, pulmonary with concomitant extrapulmon-
ary forms had similar treatment outcomes compared with pulmonary forms after adjustment
for potential confounders. At the aggregate level, reporting treatment success for all clinical
forms together might hide differences in progress between pulmonary and extrapulmonary
tuberculosis control.
Introduction
Tuberculosis (TB) is an ancient disease still responsible for a high burden and high mortality
worldwide[1]. TB can manifest in any tissue of the human body and the most common clinical
presentation of active TB is pulmonary (PTB), representing, on average, around 80–85% of
cases[1–5]. However, the proportion of extrapulmonary TB (EPTB) cases is sometimes higher
in several low, middle and high-income countries[1, 2, 6, 7]: 43% in Cambodia[1] and 53% in
England and Wales[3]. The differential distribution of some risk factors (e.g., aging and immu-
nosuppression status) in each country is partly responsible for these discrepancies between
PTB and EPTB burdens[4–6, 8]. Additionally, recent studies reported a relative increase in the
proportion of EPTB cases, attributing it to the use of new immunosuppressive therapies, avail-
ability of diagnostic methods and better control of PTB[2, 3, 7, 9].
The definitions of PTB and EPTB are inconsistent in the literature[10]. Based mainly on the
risk of transmission and guided by anatomy, the World Health Organization (WHO) classifies
all patients into two categories: PTB (i.e., pulmonary, pulmonary with concomitant extrapul-
monary, laryngeal and miliary disease) and EPTB (i.e., disease involving organs other than the
lungs)[11]. However, other definitions from international societies and national organizations
contain an extended anatomical TB classification and, additionally, report a third category
labelled disseminated TB (i.e., miliary, two or more non-contiguous extrapulmonary sites or
positive blood culture)[7, 12, 13]. This inconsistency in TB anatomical classification has direct
implications for both the interpretation of TB epidemiology and program evaluations[4, 5, 7,
10], and for treatment decisions, with potential impact on treatment outcomes[13, 14].
The variations in EPTB classification constitute a public health problem that is neither
widely recognized nor well understood. Although efforts have been made to improve diagnos-
tic methods, EPTB has been considered a neglected disease[7, 10, 15]. We conducted this
study with the primary aim of investigating whether an extended anatomical TB definition bet-
ter identifies a patient’s likelihood of an unfavourable treatment outcome. Our secondary aim
was to evaluate whether the definition impacts on the reported TB treatment outcome at the
aggregate level as a public health perspective.
Methods
Study population
We conducted an observational retrospective analysis of routinely collected tuberculosis data
from São Paulo State, Brazil on 62,178 patients with newly diagnosed TB from 2010 to 2013.
São Paulo State has around 44 million inhabitants[16] and is responsible for the highest num-
ber (20%) of TB cases in Brazil, with an estimated TB incidence of 38 per 100,000 person years
[17].
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We included patients aged15 years, newly diagnosed with TB (i.e. who had never been
treated for TB or who had taken anti-TB drugs1 month)[11] from 2010 to 2013. We
excluded presumptive TB patients whose diagnosis had changed during the follow-up period
and patients still on treatment at the time of database acquisition.
Data source
We used data from the dedicated electronic system of the São Paulo State TB Program–“Tb-
web”. This dedicated electronic platform includes all notified cases of bacteriologically or clini-
cally confirmed cases of TB from residents in São Paulo State. TB notification is compulsory
in Brazil and only notified cases can start treatment. Tbweb also receives continuous input
regarding patient and treatment status from health-care units responsible for patient care. The
platform has several steps for data quality, accuracy and consistency[17].
We had official written permission to use the data from the Data Guardians, the Health
Department of São Paulo State and Ethical Approval from the local Ethics Committee (Comitê
de E´tica em Pesquisa da Faculdade de Medicina da Universidade de São Paulo—protocol 270/
14).
Definitions
Clinical TB form: the attending clinician determined the site of the disease according to a pre-
specified list of sites (pulmonary, pleural, lymphatic, bone, genital, urinary tract, central ner-
vous system, intestinal, ocular, skin, laryngeal, other, or multiple organs/miliar). The electronic
system allowed the clinician to enter up to a maximum of three sites. Using the data available
in the database, we derived two different clinical classifications (Table 1):
Classification 1 (following the WHO classification) has two potential forms: 1) Pulmonary
(i.e., lung parenchyma, pulmonary with any concomitant extrapulmonary site, laryngeal and
miliary TB) and 2) Extrapulmonary (any other site occurrence and combinations)[11].
Classification 2 (following international societies’ classification) has four potential forms:
1) Pulmonary only, 2) Pulmonary and any concomitant extrapulmonary sites and combina-
tions, 3) Extrapulmonary only and 4) Miliary/Disseminated (disseminated defined as occur-
rence of two or more sites not including lung parenchyma and/or a positive blood culture)[4,
5, 7, 10, 13, 18, 19].
Classification 2 was our exposure of interest, because we hypothesized that it better discrim-
inates patients by their risk of worse outcomes.
Treatment outcomes: we used the 2013 WHO definitions, adapting them to the “TBweb”.
This definition consists of 6 outcomes (Table A in S1 File), grouped into treatment success
(“desired” outcomes) and unsuccessful treatment outcomes (“undesirable” outcomes).
Table 1. Two clinical classifications of active tuberculosis.
Classification 1 (WHO) Classification 2
Pulmonary (lung parenchyma) PTB PTB only
Pulmonary and any concomitant extrapulmonary forms PTB PTB + EPTB
Miliary PTB Miliary/Disseminated
Laryngeal PTB EPTB only
Extrapulmonary – 1 organ affected EPTB EPTB only
Extrapulmonary – 2 or more non-contiguous organs affected EPTB Miliary/Disseminated
Abbreviations: EPTB—extrapulmonary tuberculosis; PTB—pulmonary tuberculosis; WHO—World Health Organization
https://doi.org/10.1371/journal.pone.0187585.t001
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Treatment success is defined as the sum of “Cured” and “Treatment completed”. Briefly,
“Cured” is defined for patients with PTB with bacteriologically confirmed TB at the beginning
of treatment who had proven negative microbiological results upon treatment completion.
“Treatment completed” is defined for patients with TB who completed treatment without evi-
dence of clinical failure, but with no record to show negative microbiological results upon
treatment completion, either because tests were not done or because no biological material
was available (e.g., patient without sputum production). Unsuccessful outcomes comprised
four possible outcomes: treatment failure, death, loss to follow-up and not evaluated[11, 17].
Full description of each outcome is described on the supplementary file (Table A in S1 File).
Potential confounders: we selected a priori potential confounders to be adjusted for, includ-
ing those related to patients (age, sex, country of birth, self-reported race, homelessness,
education level, alcohol and drug use, diabetes mellitus, mental disorder, HIV status, immuno-
suppression other than HIV) and those related to disease and treatment (place of diagnosis,
chest x-ray and microbiologic status at diagnosis, initial drug scheme and directly observed-
treatment—DOT). HIV status was classified as HIV negative, positive or unknown, as recom-
mended by the WHO 2013 definitions[11].
Data analysis
We described continuous variables with mean (SD) or median [IQR], depending on the vari-
able distribution. Categorical variables were described as counts and percentage and compared
using Fisher’s exact test or a chi-square test, as appropriate.
We used logistic regression models to evaluate the impact of the four different forms of TB
disease (Classification 2) on the unsuccessful outcome of treatment (“primary outcome”) and
death (“secondary outcome”) at patient level. First, we obtained crude odds ratios (OR) with
95% confidence interval (CI). We then obtained adjusted ORs (adjOR) allowing for all the
potential confounding factors defined a priori in a multivariable logistic regression model. We
evaluated a potential interaction between our exposure and HIV status in the final model[17].
Multicollinearity was assessed by the amount of variation on the standard errors of parameters
on the logarithmic scale. To deal with missing data, we investigated the missingness patterns
among variables and described the number of missing values and their associations (Tables B
and C in S1 File). We assumed the missing values to be missing at random (MAR) and
explored whether the missing values were conditioned on observed variables, suggesting a
MAR mechanism. We did not expect a missing not at random pattern[20]. Our main analysis
was based on five multiple imputed datasets. We also report the complete case analysis in a
sensitivity analysis. For the patient level analysis, we excluded patients who were diagnosed
upon necropsy, because our aim was to evaluate TB treatment outcomes[17, 21].
We conducted two additional analyses to investigate the impact of different TB classifica-
tions on the aggregate reported data at country level for a public health perspective. We gener-
ated 500 datasets with different sample sizes, simulating different countries, by sampling our
data using bootstrapping, taking account of the four TB clinical presentations (Classification
2) and HIV status. In each dataset, we compared the difference in treatment success for each
simulated country that would be reported for pulmonary and extrapulmonary TB between the
two classifications (e.g., treatment success of PTB as defined in Classification 2 minus treat-
ment success of PTB as defined by WHO). Finally, we compared the impact on treatment suc-
cess at country level according to whether it was reported as currently recommended by WHO
(treatment success of PTB + EPTB altogether) or as PTB and EPTB separately. In both analyses
at country level, we reported the crude treatment success and the adjusted one by fitting the
final multivariate model in each dataset.
TB classification impact on treatment outcomes
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We followed the STROBE guidelines and all analyses were conducted in STATA 13.1 (Sta-
taCorp-Texas).
Results
Of 67,044 patients with newly diagnosed TB, we excluded 2,384 (3.6%) patients aged<15
years, 2,023 (3.0%) patients whose diagnosis had changed and 459 (0.7%) still on treatment.
Finally, we analyzed 62,178 patients with newly diagnosed TB from 2010 to 2013 from São
Paulo State.
General characteristics of patients and clinical presentation
Most patients were classified as PTB only (n = 49,999; 80.4%), followed by EPTB only
(n = 9,026; 14.5%). A further 1,651 (2.7%) patients had concomitant PTB-EPTB, while 1,502
(2.4%) had miliary/disseminated form (1,071–71.3% Miliary and 431–28.7% disseminated).
Table 2 describes the characteristics of patients over the four clinical presentations. Patients
with PTB only were younger, less frequently white and had lower education levels. PTB only
patients were mainly diagnosed in primary care, had higher microbiological confirmation and
higher frequency of DOT. Patients with EPTB only had the highest female/male ratio, and
lower prevalence of homelessness, alcohol and drug use. Miliary/disseminated cases were
older, had higher prevalence of HIV positive status and other immunosuppression, and were
more frequently diagnosed at necropsy. PTB-EPTB patients were nearly three times more
likely to have HIV positive status or other immunosuppression than PTB only, and were
mainly diagnosed during hospitalization.
Site of the disease
Pleural and lymphatic were the most common extrapulmonary TB sites, followed by central
nervous system. Most sites were comparable among patients with PTB-EPTB and EPTB only.
However, ocular and skin sites were more common in EPTB only compared with PTB-EPTB
(5.3% vs. 1.0% and 2.4% vs. 0.8%, p<0.001, respectively). In contrast, intestinal and laryngeal
sites were less common in EPTB only than PTB-EPTB (2.2% vs. 4.2% and 0.6% vs. 5.4%,
p<0.001, respectively) (Fig 1).
Treatment outcomes at patient level
The overall percentage of unsuccessful outcome of treatment was 18.9% (n = 11,744), mainly
due to losses to follow-up (9.7%) and death (7.9%). EPTB only had the highest rate of treat-
ment success (84.0%), followed by PTB only (81.5%), PTB-EPTB (73.2%) and miliary/dissemi-
nated (58.6%). Losses to follow-up were equally distributed (around 10%) among clinical
forms, except for EPTB only at 7.5%. PTB-EPTB patients had two times higher mortality
(14.2%) than PTB only and EPTB only, whereas miliary/disseminated had around four times
higher mortality (30.8%). Table 3 shows the treatment outcomes for all patients stratified by
different classifications.
The crude and adjusted associations between clinical forms and unsuccessful outcomes are
shown in Table 4. EPTB only had lower odds of unsuccessful outcome of treatment and death
compared with PTB only (adjOR 0.65, 95% CI, 0.60–0.71, p<0.001 and adjOR 0.59, 95% CI,
0.52–0.67, p<0.001, respectively). In contrast, miliary/disseminated were positively associated
with unsuccessful outcome of treatment and death compared with PTB only (adjOR 1.51, 95%
CI, 1.33–1.71, p<0.001 and adjOR 1.99, 95% CI, 1.72–2.31, p<0.001, respectively). However,
PTB-EPTB had similar odds to unsuccessful outcome of treatment and death than PTB only
TB classification impact on treatment outcomes
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Table 2. Comparison of general characteristics of patients newly diagnosed with tuberculosis classified in four clinical forms (n = 62,178).
Variable Values Pulmonary
TB
(n = 49,999)
Pulmonary and
Extrapulmonary
TB (n = 1,651)
Extrapulmonary
TB (n = 9,026)
Miliary/
Disseminated
TB (n = 1,502)
P value
Age, years 15–25 10,305
(20.6%)
249 (15.1%) 1,520 (16.9%) 153 (10.2%) <0.001
25.1–35 13,414
(26.9%)
436 (26.4%) 2,312 (25.6%) 350 (23.3%)
35.1–45 9,593 (19.2%) 384 (23.3%) 1,988 (22.0%) 432 (28.8%)
45.1–55 8,218 (16.5%) 292 (17.7%) 1,484 (16.5%) 278 (18.5%)
55.1–65 4,963 (9.9%) 175 (10.6%) 940 (10.4%) 161 (10.7%)
65.1–75 2,262 (4.5%) 79 (4.8%) 478 (5.3%) 75 (5.0%)
75.1–85 981 (2.0%) 32 (1.9%) 230 (2.6%) 44 (2.9%)
85.1–105 211 (0.4%) 4 (0.2%) 68 (0.8%) 7 (0.5%)
Missing 52 (0.1%) - 6 (0.1%) 2 (0.1%)
Sex Female 13,935
(27.9%)
512 (31.0%) 3,634 (40.3%) 463 (30.8%) <0.001
Male 36,064
(72.1%)
1,139 (69.0%) 5,392 (59.7%) 1,039 (69.2%)
Country of birth Brazil 41,557
(97.3%)
1,370 (96.8%) 7,536 (97.7%) 1,211 (97.4%) 0.124
Not Brazil 1,177 (2.7%) 45 (3.2%) 180 (2.3%) 32 (2.6%)
Missing 7,265 (14.5%) 236 (14.3%) 1,310 (14.5%) 259 (17.2%)
Self-reported race White 22,119
(51.0%)
841 (56.2%) 4,646 (58.1%) 794 (58.6%) <0.001
Black 5,085 (11.7%) 171 (11.4%) 872 (10.9%) 182 (13.4%)
Brown/Mixed 15,361
(35.4%)
459 (30.7%) 2,333 (29.2%) 363 (26.8%)
Asian 452 (1.0%) 21 (1.4%) 117 (1.5%) 12 (0.9%)
Indigenous 353 (0.8%) 5 (0.3%) 33 (0.4%) 5 (0.4%)
Missing 6,629 (13.3%) 154 (9.3%) 1,025 (11.4%) 146 (9.7%)
Education Illiterate 1,591 (3.9%) 41 (3.2%) 199 (2.8%) 39 (3.6%) <0.001
1–3 years 4,879 (12.1%) 122 (9.5%) 598 (8.3%) 116 (10.6%)
4–7 years 15,488
(38.4%)
428 (33.2%) 2,071 (28.6%) 404 (36.7%)
8–11 years 14,864
(36.8%)
540 (41.8%) 3,136 (43.3%) 417 (37.9%)
12–14 years 2,468 (6.1%) 110 (8.5%) 774 (10.7%) 67 (6.1%)
15 years 1,094 (2.7%) 50 (3.9%) 464 (6.4%) 57 (5.2%)
Missing 9,615 (19.2%) 360 (21.8%) 1,784 (19.8%) 402 (26.8%)
Homelessness No 48,616
(97.2%)
1,610 (97.5%) 8,962 (99.3%) 1,458 (97.1%) <0.001
Yes 1,383 (2.8%) 41 (2.5%) 64 (0.7%) 44 (2.9%)
Alcohol No 42,138
(84.3%)
1,395 (84.5%) 8,349 (92.5%) 1,281 (85.3%) <0.001
Yes 7,861 (15.7%) 256 (15.5%) 677 (7.5%) 221 (14.7%)
Diabetes mellitus No 46,858
(93.7%)
1,567 (94.9%) 8,617 (95.5%) 1,439 (95.8%) <0.001
Yes 3,141 (6.3%) 84 (5.1%) 409 (4.5%) 63 (4.2%)
Drug user No 44,459
(88.9%)
1,487 (90.1%) 8,609 (95.4%) 1,357 (90.3%) <0.001
Yes 5,540 (11.1%) 164 (9.9%) 417 (4.6%) 145 (9.7%)
(Continued )
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after adjusting for potential confounders. Similar results were found in the complete case anal-
ysis (Table D in S1 File). We did not find an effect modification between the extended anatom-
ical classification and HIV status.
Treatment success at country-level
The average characteristics of the 500 samples (“500 countries”) are described in Table E in
S1 File. The median sample size was 60,781 patients [36,447–88,689], with minimum 10,935
Table 2. (Continued)
Variable Values Pulmonary
TB
(n = 49,999)
Pulmonary and
Extrapulmonary
TB (n = 1,651)
Extrapulmonary
TB (n = 9,026)
Miliary/
Disseminated
TB (n = 1,502)
P value
Mental disorder No 49,061
(98.1%)
1,610 (97.5%) 8,871 (98.3%) 1,467 (97.7%) 0.102
Yes 938 (1.9%) 41 (2.5%) 155 (1.7%) 35 (2.3%)
HIV status Negative 38,470
(76.9%)
993 (60.2%) 6,370 (70.6%) 684 (45.5%) <0.001
Positive 4,364 (8.7%) 461 (27.9%) 1,389 (15.4%) 633 (42.1%)
Unknown 7,165 (14.3%) 197 (11.9%) 1,267 (14.0%) 185 (12.3%)
Other immunosuppression No 49,616
(99.2%)
1,614 (97.8%) 8,875 (98.3%) 1,463 (97.4%) <0.001
Yes 383 (0.8%) 37 (2.2%) 151 (1.7%) 39 (2.6%)
Place of diagnosis PHC/Ambulatory 31,929
(64.8%)
568 (34.6%) 3,963 (44.6%) 420 (28.3%) <0.001
Emergency service 10,699
(21.7%)
385 (23.5%) 1,733 (19.5%) 338 (22.8%)
Hospital 6,148 (12.5%) 670 (40.9%) 3,104 (35.0%) 638 (43.0%)
Necropsy 512 (1.0%) 17 (1.0%) 79 (0.9%) 88 (5.9%)
Missing 711 (1.4%) 11 (0.7%) 147 (1.6%) 18 (1.2%)
Microbiological status Negative 6,790 (14.3%) 486 (32.8%) 4,218 (72.8%) 611 (51.0%) <0.001
Positive 40,861
(85.7%)
996 (67.2%) 1,580 (27.3%) 586 (49.0%)
Missing 1,836 (3.7%) 152 (9.3%) 3,149 (35.2%) 217 (15.4%)
Chest-X-ray Not done 7,782 (16.4%) 117 (7.4%) 1,572 (18.8%) 120 (8.9%) <0.001
Normal 1,718 (3.6%) 87 (5.5%) 2,342 (28.0%) 166 (12.4%)
Additional pathology 178 (0.4%) 24 (1.5%) 291 (3.5%) 30 (2.2%)
Suspect of TB 28,146
(59.5%)
1,154 (73.0%) 3,960 (47.3%) 928 (69.1%)
Suspect of TB +
cavitation
9,503 (20.1%) 198 (12.5%) 206 (2.5%) 100 (7.4%)
Missing 2,160 (4.4%) 54 (3.3%) 576 (6.4%) 70 (5.0%)
Initial drug scheme Other 898 (1.8%) 59 (3.6%) 249 (2.8%) 58 (4.1%) <0.001
RHZ 489 (1.0%) 16 (1.0%) 111 (1.2%) 19 (1.3%)
RHZE 48,100
(97.2%)
1,559 (95.4%) 8,587 (96.0%) 1,337 (94.6%)
Directly observed treatment-
DOT
No 11,892
(24.1%)
733 (45.2%) 3,687 (41.5%) 622 (44.5%) <0.001
Yes 37,352
(75.9%)
890 (54.8%) 5,204 (58.5%) 775 (55.5%)
Missing 243 (0.5%) 11 (0.7%) 56 (0.6%) 17 (1.2%)
Abbreviations: PHC–primary health care clinic; R–rifampicin; H–isoniazid; Z–pyrazinamide; E—ethambutol
https://doi.org/10.1371/journal.pone.0187585.t002
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cases and maximum 165,641 cases. We found considerable variability in the distribution of the
four clinical forms of TB and HIV status.
The differences in treatment success that would be reported depending on whether each
country reported PTB or EPTB only (Classification 2) instead of PTB or EPTB as Classification
1 are shown in Fig 2. Although the average differences would be around 1 or 2% (Fig 2;
Table F in S1 File), for individual countries we can observe important differences. For instance,
we observed 5 countries where the treatment success for “PTB only” would be over or underes-
timated by more than 5% (Table G in Si File). A country with 68% PTB and 32% EPTB (Classi-
fication 1) and high prevalence of HIV, would have reported a crude difference of 7.87% for
PTB. Similarly, a country with 96.5% of PTB and 3.5% of EPTB (Classification 1) and low prev-
alence of HIV, would have reported a crude difference of 6.83% for EPTB (Fig 2, Table G in
S1 File). The expected adjusted differences are shown in Fig A, Tables F and G in S1 File.
The differences in treatment success that would be reported if each country reports PTB
and EPTB (Classification 1) separately instead of the overall rate between PTB and EPTB
together are shown in Fig 3, Fig B and Table H in S1 File. We observed gaps between the treat-
ment success achieved for each form (PTB or EPTB) and the treatment success of both forms
Fig 1. Prevalence distribution of extrapulmonary sites in patients with newly diagnosed tuberculosis presenting concurrent
pulmonary or only extrapulmonary disease.
https://doi.org/10.1371/journal.pone.0187585.g001
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together as evaluated by the WHO. Although the average gap was more evident for countries
with a lower proportion of PTB, there were also huge gaps for individual countries with a high
proportion of PTB. For instance, in a country with 60% PTB, the treatment success for both
forms was 10% higher than that observed for PTB. There were 60 (12%) countries for PTB
and 181 (36.2%) for EPTB where this gap would be more than 10% (Table I in S1 File). The
expected adjusted differences are shown in Fig C, Tables H and I in S1 File.
Discussion
We report three important findings regarding the impact of different clinical classifications of
new TB cases. We demonstrated that the clinical classification had a strong association with
treatment outcomes at the patient level. We showed that the difference in the reported treat-
ment success at the country level would have a minor impact whether reporting PTB as
Table 3. Treatment outcomes stratified by Classification 1 and 2 for newly diagnosed tuberculosis in São Paulo State, Brazil.
Classification 1 (WHO) Classification 2
Outcomes Overall
(n = 62,178)
PTB
(n = 52,773)
EPTB
(n = 7,810)
PTB only
(n = 49,999)
PTB-EPTB
(n = 1,651)
EPTB only
(n = 9,026)
Miliary/ Disseminated
TB (n = 1,502)
Treatment success 50,434
(81.1%)
42,624
(80.8%)
7,810
(83.0%)
40,761
(81.5%)
1,208
(73.2%)
7,585
(84.0%)
880
(58.6%)
Unsuccessful outcome 11,744
(18.9%)
10,149
(19.2%)
1,595
(17.0%)
9,238
(18.5%)
443
(26.8%)
1,441
(16.0%)
622
(41.4%)
Treatment failure 306
(0.5%)
302
(0.6%)
4
(0.1%)
285
(0.6%)
13
(0.8%)
3
(0.1%)
5
(0.3%)
Death 4,925
(7.9%)
4,115
(7.8%)
810
(8.6%)
3,526
(7.1%)
235
(14.2%)
702
(7.8%)
462
(30.8%)
Loss to follow-up 6,003
(9.7%)
5,283
(10.0%)
720
(7.7%)
5,003
(10.0%)
176
(10.7%)
679
(7.5%)
145
(9.7%)
Not evaluated 510
(0.8%)
449
(0.9%)
61
(0.7%)
424
(0.9%)
19
(1.2%)
57
(0.6%)
10
(0.7%)
Abbreviations: EPTB—extrapulmonary tuberculosis; PTB—pulmonary tuberculosis; WHO—World Health Organization
https://doi.org/10.1371/journal.pone.0187585.t003
Table 4. Crude and adjusted associations between clinical forms of TB and unsuccessful outcome of treatment and death (n = 62,178).
Variable Unsuccessful outcome of treatment Death
Crude Crude OR (95% CI) P value Crude OR (95% CI) P value
Pulmonary TB Reference Reference
Pulmonary and Extrapulmonary TB 1.65 (1.47–1.84) <0.001 2.37 (2.05–2.75) <0.001
Extrapulmonary TB 0.84 (0.79–0.89) <0.001 1.15 (1.06–1.26) 0.002
Miliary/Disseminated TB 2.84 (2.54–3.16) <0.001 5.55 (4.90–6.28) <0.001
Adjusted* Adjust. OR (95% CI) P value Adjust OR (95% CI) P value
Pulmonary TB Reference Reference
Pulmonary and Extrapulmonary TB 1.00 (0.88–1.13) 0.941 1.05 (0.89–1.24) 0.591
Extrapulmonary TB 0.65 (0.60–0.71) <0.001 0.59 (0.52–0.67) <0.001
Miliary/Disseminated TB 1.51 (1.33–1.71) <0.001 1.99 (1.72–2.31) <0.001
*Adjusted for age, sex, country of birth, race, education, homelessness, alcohol and drugs use, diabetes, mental disorder, HIV status, other
immunosuppression, place of diagnosis, microbiologic diagnosis, Chest-X-Ray pattern at diagnosis, initial treatment drug and initial offer of directly
observed treatment. Adjusted model from 5 multiple imputed datasets.
Abbreviations: CI—confidence intervals; OR—odds ratios; TB—tuberculosis.
https://doi.org/10.1371/journal.pone.0187585.t004
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Classification 1 (WHO) compared with PTB only as Classification 2. However, we showed that
reporting the treatment success of both forms as currently recommended hides any difference
in progress in PTB and EPTB. This has direct implications for national programs, because
PTB is the main source of transmission, and in some countries the treatment success rate for
PTB is lower than the overall success reported.
EPTB has rarely been studied; and when it is studied, the focus is on risk factors for EPTB
[4, 5] and diagnostic methods[2], and few studies focused on treatment outcomes of EPTB
[22]. One main barrier to interpreting previous studies is the lack of consistency between the
clinical classifications used. Some reports excluded cases with pulmonary and concomitant
extrapulmonary TB, others studied each form separately or mixed the disseminated forms into
pulmonary or extrapulmonary classification[4, 8, 10]. In this study, we analyzed all forms
Fig 2. Over or underestimation in tuberculosis treatment success between the two clinical classifications at country level for 500
simulated countries. Panel A: difference in treatment success between Pulmonary TB only minus Pulmonary TB as classified by WHO
(Classification 1); Panel B: difference in treatment success between Extrapulmonary TB only minus Extrapulmonary TB as classified by
WHO (Classification 1).
https://doi.org/10.1371/journal.pone.0187585.g002
Fig 3. Over or underestimation in tuberculosis treatment success at country level for 500 simulated countries between overall
(both forms) and each form of tuberculosis as classified by WHO (Classification 1). Panel A: Average treatment success for both
forms, pulmonary and extrapulmonary tuberculosis; Panel B: difference in treatment success between overall (both forms) minus pulmonary
TB as classified by WHO (Classification 1).
https://doi.org/10.1371/journal.pone.0187585.g003
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classified in a proposed extended classification. Using this classification, we showed that after
adjustments for potential confounders, patients with PTB only and PTB-EPTB had a very sim-
ilar percentage of unsuccessful outcome of treatment and death. This was unexpected, requires
replication and shows the importance of not excluding these patients from observational stud-
ies. In contrast, patients with EPTB only (mainly pleural and lymphatic disease) had better
treatment outcomes. Current treatment guidelines have few evidence-based indications of cus-
tomized treatment for different forms of TB, and it is likely that approaching TB treatment,
taking into account its clinical presentation, will have an impact on treatment decisions and
outcomes[13, 23, 24].
Miliary presentation is a classical form of TB defined by diffuse miliar infiltration on chest-
X-ray and is attributed to a massive lymphohaematogeneous dissemination of the bacilli[25].
Although some classifications and clinicians still focus on the chest-X-ray pattern to classify
miliary TB, it is well known that chest-X-ray has low sensitivity to diagnose diffuse microno-
dules[25, 26]. In addition, other forms of disseminated TB (also labelled bacteraemic, cryptic
or generalized) have similar pathophysiology of miliary TB, with challenging diagnosis and
paucity of symptoms, leading to delayed treatment and worse outcomes[25, 27, 28]. We
showed that although a great part of the association between miliary/disseminated TB and
worse outcomes was due to confounding factors, disseminated forms were still associated with
unsuccessful outcome of treatment and death. We believe it should be a priority to treat dis-
seminated forms of TB separately in official reports, guidelines and clinical studies, due to
their particular features and worse outcomes.
The extended anatomical classification is likely to be applicable in clinical practice because
it is simple and based on normally collected data in National TB Programs. However, it does
not encompass other important features present in the complex pathogen-host interaction
[29]. Indeed, the classification does not take account markers of immune response, or addi-
tional characteristics such as bacillary burden, and radiological pattern for pulmonary cases
[29, 30]. Similarly, HIV positive patients deserve special attention, because of their expected
worse outcomes and their TB clinical presentation, that could be unusual, limiting our
extended “classical” anatomic classification. We did not observe an effect modification for
HIV status, however we have not data about HIV stage (e.g., CD4 count and viral load) and
antiretroviral therapy[31]. We believe that taking into account all these other important fea-
tures, as well as using data-driven techniques in our “Big data era” (e.g., latent-variable analysis
or machine learning)[32], a new classification based on clusters and phenotypes might show
better performance compared with the extended anatomical classification.
TB remains a major public health problem and, although improvements have been
observed in recent decades, the goals regarding TB control have not been achieved[1, 33]. In
particular, several countries, including Brazil, did not achieve the expected treatment success
rate of 85% recommended by WHO[1]. Since PTB is the main source of transmission, national
TB programs should ensure that targets are monitored for these patients to decrease the risk of
transmission. We hypothesized that reporting the overall treatment success (PTB+EPTB), as
requested by the WHO, could hinder accurate monitoring of PTB, thereby distorting the eval-
uation of national programs. Our results clearly showed that both over and underestimation of
treatment success for PTB and EPTB can happen in several scenarios when using the WHO
classification at the aggregate level. Although some of the simulated scenarios are unlikely to
occur (such as countries with less than 40% of PTB), a substantial percentage of countries
could be reporting10% difference in treatment success rates for PTB. Importantly, we
showed that we have small changes in treatment success if reporting PTB only (Classification
2) instead of PTB as in Classification 1. The difference is expected to be small as PTB only is
the major form of PTB in Classification 1, while other forms contribute very few cases, and
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poor outcomes occurred mainly in miliary disease, which corresponds to less than 2% of cases.
WHO leaves the decision of whether to report treatment outcomes separately for PTB and
EPTB to national programs[34].
We suggest, based on our results, that WHO should require all countries to analyze and
report treatment outcomes separately for PTB and for EPTB. Indeed, the Centers for Dis-
ease Control and Prevention (CDC), the European Centre for Disease Prevention and Con-
trol (ECDC) and some national programs (e.g., Public Health England) already report TB
epidemiology using an approach similar to the extended classification (Classification 2)[12,
19].
Our study used population-representative data from a high-burden country. We overcame
previous literature limitations by including in our analysis the four clinical forms of TB. Addi-
tionally, we showed that reports and audits from national programs could be improved by sep-
arating treatment outcomes into TB forms. However, our study has some limitations. We
included only new cases of TB in order to analyze a homogeneous population, but WHO con-
siders both relapses and new cases to evaluate treatment outcomes. Further studies should
assess the association of the extended anatomical classification and treatment outcomes in dif-
ferent settings, and not only in new cases, but also including relapses. Second, we used the
standardized treatment outcomes as suggested by the WHO, but previous studies showed the
impact on treatment success rate using different treatment outcomes classification[21]. The
impact of the extended anatomical classification on treatment outcomes should be evaluated
using other treatment outcomes definitions. Indeed, there is a gap on how to appropriately
evaluate treatment outcomes for EPTB, and further research should focus on it, for a feasible
and comparable treatment outcome definitions. Third, we excluded TB cases in children, a
population where disseminated TB has an important impact on treatment outcomes. Fourth,
we did not evaluate the treatment outcome for the EPTB group stratifying by each site (e.g.,
renal, adrenal, central nervous system). The fact that some sites have particular natural courses,
such as long quiescent times, might explain in part our findings for better outcomes for EPTB.
Finally, our main analysis was based on multiple imputation assuming a missing at random
mechanism, that is an untestable assumption. However, we have not indications of missing
not at random mechanism, based on the missingness pattern and on the researcher’s experi-
ence with the São Paulo TB database. Importantly, our results remained similar in our sensitiv-
ity analysis.
In summary, we observed that the anatomical classification of TB was strongly associated
with treatment outcomes. We hope our results will encourage a discussion of how to better
address the classification of TB for individual treatment and for public health reporting by the
international community responsible for establishing policies, guidelines recommendations,
research and for monitoring TB indicators.
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